Skip to main content
Erschienen in: Breast Cancer Research and Treatment 1/2018

14.09.2017 | Epidemiology

Exome array analysis identifies ETFB as a novel susceptibility gene for anthracycline-induced cardiotoxicity in cancer patients

verfasst von: Sara Ruiz-Pinto, Guillermo Pita, Miguel Martín, Teresa Alonso-Gordoa, Daniel R. Barnes, María R. Alonso, Belén Herraez, Purificación García-Miguel, Javier Alonso, Antonio Pérez-Martínez, Antonio J. Cartón, Federico Gutiérrez-Larraya, José A. García-Sáenz, Javier Benítez, Douglas. F. Easton, Ana Patiño-García, Anna González-Neira

Erschienen in: Breast Cancer Research and Treatment | Ausgabe 1/2018

Einloggen, um Zugang zu erhalten

Abstract

Purpose

Anthracyclines are widely used chemotherapeutic drugs that can cause progressive and irreversible cardiac damage and fatal heart failure. Several genetic variants associated with anthracycline-induced cardiotoxicity (AIC) have been identified, but they explain only a small proportion of the interindividual differences in AIC susceptibility.

Methods

In this study, we evaluated the association of low-frequency variants with risk of chronic AIC using the Illumina HumanExome BeadChip array in a discovery cohort of 61 anthracycline-treated breast cancer patients with replication in a second independent cohort of 83 anthracycline-treated pediatric cancer patients, using gene-based tests (SKAT-O).

Results

The most significant associated gene in the discovery cohort was ETFB (electron transfer flavoprotein beta subunit) involved in mitochondrial β-oxidation and ATP production (P = 4.16 × 10−4) and this association was replicated in an independent set of anthracycline-treated cancer patients (P = 2.81 × 10−3). Within ETFB, we found that the missense variant rs79338777 (p.Pro52Leu; c.155C > T) made the greatest contribution to the observed gene association and it was associated with increased risk of chronic AIC in the two cohorts separately and when combined (OR 9.00, P = 1.95 × 10−4, 95% CI 2.83–28.6).

Conclusions

We identified and replicated a novel gene, ETFB, strongly associated with chronic AIC independently of age at tumor onset and related to anthracycline-mediated mitochondrial dysfunction. Although experimental verification and further studies in larger patient cohorts are required to confirm our finding, we demonstrated that exome array data analysis represents a valuable strategy to identify novel genes contributing to the susceptibility to chronic AIC.
Anhänge
Nur mit Berechtigung zugänglich
Literatur
5.
Zurück zum Zitat Von Hoff DD, Layard MW, Basa P et al (1979) Risk factors for doxorubicin-induced congestive heart failure. Ann Intern Med 91:710–717CrossRef Von Hoff DD, Layard MW, Basa P et al (1979) Risk factors for doxorubicin-induced congestive heart failure. Ann Intern Med 91:710–717CrossRef
7.
Zurück zum Zitat Blanco JG, Leisenring WM, Gonzalez-Covarrubias VM et al (2008) Genetic polymorphisms in the carbonyl reductase 3 gene CBR3 and the NAD(P)H:quinone oxidoreductase 1 gene NQO1 in patients who developed anthracycline-related congestive heart failure after childhood cancer. Cancer 112:2789–2795. doi:10.1002/cncr.23534 CrossRefPubMed Blanco JG, Leisenring WM, Gonzalez-Covarrubias VM et al (2008) Genetic polymorphisms in the carbonyl reductase 3 gene CBR3 and the NAD(P)H:quinone oxidoreductase 1 gene NQO1 in patients who developed anthracycline-related congestive heart failure after childhood cancer. Cancer 112:2789–2795. doi:10.​1002/​cncr.​23534 CrossRefPubMed
8.
Zurück zum Zitat Rajić V, Aplenc R, Debeljak M et al (2009) Influence of the polymorphism in candidate genes on late cardiac damage in patients treated due to acute leukemia in childhood. Leuk Lymphoma 50:1693–1698CrossRefPubMed Rajić V, Aplenc R, Debeljak M et al (2009) Influence of the polymorphism in candidate genes on late cardiac damage in patients treated due to acute leukemia in childhood. Leuk Lymphoma 50:1693–1698CrossRefPubMed
9.
Zurück zum Zitat Rossi D, Rasi S, Franceschetti S et al (2009) Analysis of the host pharmacogenetic background for prediction of outcome and toxicity in diffuse large B-cell lymphoma treated with R-CHOP21. Leukemia 23:1118–1126. doi:10.1038/leu.2008.398 CrossRefPubMed Rossi D, Rasi S, Franceschetti S et al (2009) Analysis of the host pharmacogenetic background for prediction of outcome and toxicity in diffuse large B-cell lymphoma treated with R-CHOP21. Leukemia 23:1118–1126. doi:10.​1038/​leu.​2008.​398 CrossRefPubMed
10.
Zurück zum Zitat Blanco JG, Sun C-L, Landier W et al (2012) Anthracycline-related cardiomyopathy after childhood cancer: role of polymorphisms in carbonyl reductase genes–a report from the Children’s Oncology Group. J Clin Oncol 30:1415–1421. doi:10.1200/JCO.2011.34.8987 CrossRefPubMed Blanco JG, Sun C-L, Landier W et al (2012) Anthracycline-related cardiomyopathy after childhood cancer: role of polymorphisms in carbonyl reductase genes–a report from the Children’s Oncology Group. J Clin Oncol 30:1415–1421. doi:10.​1200/​JCO.​2011.​34.​8987 CrossRefPubMed
11.
Zurück zum Zitat Semsei AF, Erdelyi DJ, Ungvari I et al (2012) ABCC1 polymorphisms in anthracycline-induced cardiotoxicity in childhood acute lymphoblastic leukaemia. Cell Biol Int 36:79–86. doi:10.1042/CBI20110264 CrossRefPubMed Semsei AF, Erdelyi DJ, Ungvari I et al (2012) ABCC1 polymorphisms in anthracycline-induced cardiotoxicity in childhood acute lymphoblastic leukaemia. Cell Biol Int 36:79–86. doi:10.​1042/​CBI20110264 CrossRefPubMed
14.
Zurück zum Zitat Volkan-Salanci B, Aksoy H, Kiratli PÖ et al (2012) The relationship between changes in functional cardiac parameters following anthracycline therapy and carbonyl reductase 3 and glutathione S transferase Pi polymorphisms. J Chemother 24:285–291. doi:10.1179/1973947812Y.0000000037 CrossRefPubMed Volkan-Salanci B, Aksoy H, Kiratli PÖ et al (2012) The relationship between changes in functional cardiac parameters following anthracycline therapy and carbonyl reductase 3 and glutathione S transferase Pi polymorphisms. J Chemother 24:285–291. doi:10.​1179/​1973947812Y.​0000000037 CrossRefPubMed
15.
Zurück zum Zitat Armenian SH, Ding Y, Mills G et al (2013) Genetic susceptibility to anthracycline-related congestive heart failure in survivors of haematopoietic cell transplantation. Br J Haematol 163:205–213. doi:10.1111/bjh.12516 PubMedPubMedCentral Armenian SH, Ding Y, Mills G et al (2013) Genetic susceptibility to anthracycline-related congestive heart failure in survivors of haematopoietic cell transplantation. Br J Haematol 163:205–213. doi:10.​1111/​bjh.​12516 PubMedPubMedCentral
19.
Zurück zum Zitat Visscher H, Ross CJD, Rassekh SR et al (2013) Validation of variants in SLC28A3 and UGT1A6 as genetic markers predictive of anthracycline-induced cardiotoxicity in children. Pediatr Blood Cancer 60:1375–1381. doi:10.1002/pbc.24505 CrossRefPubMed Visscher H, Ross CJD, Rassekh SR et al (2013) Validation of variants in SLC28A3 and UGT1A6 as genetic markers predictive of anthracycline-induced cardiotoxicity in children. Pediatr Blood Cancer 60:1375–1381. doi:10.​1002/​pbc.​24505 CrossRefPubMed
20.
Zurück zum Zitat Vivenza D, Feola M, Garrone O et al (2013) Role of the renin-angiotensin-aldosterone system and the glutathione S-transferase Mu, Pi and Theta gene polymorphisms in cardiotoxicity after anthracycline chemotherapy for breast carcinoma. Int J Biol Markers 28:e336–e347. doi:10.5301/jbm.5000041 CrossRefPubMed Vivenza D, Feola M, Garrone O et al (2013) Role of the renin-angiotensin-aldosterone system and the glutathione S-transferase Mu, Pi and Theta gene polymorphisms in cardiotoxicity after anthracycline chemotherapy for breast carcinoma. Int J Biol Markers 28:e336–e347. doi:10.​5301/​jbm.​5000041 CrossRefPubMed
23.
Zurück zum Zitat Krajinovic M, Elbared J, Drouin S et al (2015) Polymorphisms of ABCC5 and NOS3 genes influence doxorubicin cardiotoxicity in survivors of childhood acute lymphoblastic leukemia. Pharmacogenomics J. doi:10.1038/tpj.2015.63 PubMed Krajinovic M, Elbared J, Drouin S et al (2015) Polymorphisms of ABCC5 and NOS3 genes influence doxorubicin cardiotoxicity in survivors of childhood acute lymphoblastic leukemia. Pharmacogenomics J. doi:10.​1038/​tpj.​2015.​63 PubMed
24.
Zurück zum Zitat Visscher H, Rassekh SR, Sandor GS et al (2015) Genetic variants in SLC22A17 and SLC22A7 are associated with anthracycline-induced cardiotoxicity in children. Pharmacogenomics 16:1065–1076. doi:10.2217/pgs.15.61 CrossRefPubMed Visscher H, Rassekh SR, Sandor GS et al (2015) Genetic variants in SLC22A17 and SLC22A7 are associated with anthracycline-induced cardiotoxicity in children. Pharmacogenomics 16:1065–1076. doi:10.​2217/​pgs.​15.​61 CrossRefPubMed
25.
26.
Zurück zum Zitat Hertz DL, Caram MV, Kidwell KM et al (2016) Evidence for association of SNPs in ABCB1 and CBR3, but not RAC2, NCF4, SLC28A3 or TOP2B, with chronic cardiotoxicity in a cohort of breast cancer patients treated with anthracyclines. Pharmacogenomics 17:231–240. doi:10.2217/pgs.15.162 CrossRefPubMedPubMedCentral Hertz DL, Caram MV, Kidwell KM et al (2016) Evidence for association of SNPs in ABCB1 and CBR3, but not RAC2, NCF4, SLC28A3 or TOP2B, with chronic cardiotoxicity in a cohort of breast cancer patients treated with anthracyclines. Pharmacogenomics 17:231–240. doi:10.​2217/​pgs.​15.​162 CrossRefPubMedPubMedCentral
30.
Zurück zum Zitat Clinical trial “Genetic Expression and Prediction of Response to Neoadjuvant Docetaxel or Doxorubicin in Locally Advanced Breast Cancer”, identifier code: NCT00123929, https://clinicaltrials.gov Clinical trial “Genetic Expression and Prediction of Response to Neoadjuvant Docetaxel or Doxorubicin in Locally Advanced Breast Cancer”, identifier code: NCT00123929, https://​clinicaltrials.​gov
32.
Zurück zum Zitat Gonzalez-Neira A, Ruiz-Pinto S, Pita G., Patiño-García A Exome array analysis identifies GPR35 as a novel susceptibility gene for anthracycline-induced cardiotoxicity in childhood cancer Gonzalez-Neira A, Ruiz-Pinto S, Pita G., Patiño-García A Exome array analysis identifies GPR35 as a novel susceptibility gene for anthracycline-induced cardiotoxicity in childhood cancer
33.
Zurück zum Zitat U.S. Department of Health and Human services, National Cancer Institute. Cancer therapy Evaluation program-Common terminology Criteria for Adverse Events (CTCAE)-version 4.0. 2010 U.S. Department of Health and Human services, National Cancer Institute. Cancer therapy Evaluation program-Common terminology Criteria for Adverse Events (CTCAE)-version 4.0. 2010
35.
Zurück zum Zitat Price AL, Patterson NJ, Plenge RM et al (2006) Principal components analysis corrects for stratification in genome-wide association studies. Nat Genet 38:904–909. doi:10.1038/ng1847 CrossRefPubMed Price AL, Patterson NJ, Plenge RM et al (2006) Principal components analysis corrects for stratification in genome-wide association studies. Nat Genet 38:904–909. doi:10.​1038/​ng1847 CrossRefPubMed
46.
47.
Zurück zum Zitat Huyghe JR, Jackson AU, Fogarty MP et al (2013) Exome array analysis identifies new loci and low-frequency variants influencing insulin processing and secretion. Nat Genet 45:197–201. doi:10.1038/ng.2507 CrossRefPubMed Huyghe JR, Jackson AU, Fogarty MP et al (2013) Exome array analysis identifies new loci and low-frequency variants influencing insulin processing and secretion. Nat Genet 45:197–201. doi:10.​1038/​ng.​2507 CrossRefPubMed
Metadaten
Titel
Exome array analysis identifies ETFB as a novel susceptibility gene for anthracycline-induced cardiotoxicity in cancer patients
verfasst von
Sara Ruiz-Pinto
Guillermo Pita
Miguel Martín
Teresa Alonso-Gordoa
Daniel R. Barnes
María R. Alonso
Belén Herraez
Purificación García-Miguel
Javier Alonso
Antonio Pérez-Martínez
Antonio J. Cartón
Federico Gutiérrez-Larraya
José A. García-Sáenz
Javier Benítez
Douglas. F. Easton
Ana Patiño-García
Anna González-Neira
Publikationsdatum
14.09.2017
Verlag
Springer US
Erschienen in
Breast Cancer Research and Treatment / Ausgabe 1/2018
Print ISSN: 0167-6806
Elektronische ISSN: 1573-7217
DOI
https://doi.org/10.1007/s10549-017-4497-9

Weitere Artikel der Ausgabe 1/2018

Breast Cancer Research and Treatment 1/2018 Zur Ausgabe

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.